TW202207919A - 脂肪性肝疾患的治療用醫藥 - Google Patents

脂肪性肝疾患的治療用醫藥 Download PDF

Info

Publication number
TW202207919A
TW202207919A TW110118449A TW110118449A TW202207919A TW 202207919 A TW202207919 A TW 202207919A TW 110118449 A TW110118449 A TW 110118449A TW 110118449 A TW110118449 A TW 110118449A TW 202207919 A TW202207919 A TW 202207919A
Authority
TW
Taiwan
Prior art keywords
formula
pharmaceutical composition
fatty liver
liver disease
treatment
Prior art date
Application number
TW110118449A
Other languages
English (en)
Chinese (zh)
Inventor
雪岡日出男
島崎淳行
濱田忠輝
Original Assignee
日商鹽野義製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商鹽野義製藥股份有限公司 filed Critical 日商鹽野義製藥股份有限公司
Publication of TW202207919A publication Critical patent/TW202207919A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110118449A 2020-05-21 2021-05-21 脂肪性肝疾患的治療用醫藥 TW202207919A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020089196 2020-05-21
JP2020-089196 2020-05-21
JP2020134338 2020-08-07
JP2020-134338 2020-08-07

Publications (1)

Publication Number Publication Date
TW202207919A true TW202207919A (zh) 2022-03-01

Family

ID=78707930

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110118449A TW202207919A (zh) 2020-05-21 2021-05-21 脂肪性肝疾患的治療用醫藥

Country Status (10)

Country Link
US (2) US12521375B2 (https=)
EP (1) EP4154880A4 (https=)
JP (1) JP7820294B2 (https=)
KR (1) KR20230013126A (https=)
CN (1) CN115666558A (https=)
AU (1) AU2021275292A1 (https=)
CA (1) CA3182134A1 (https=)
MX (1) MX2022014553A (https=)
TW (1) TW202207919A (https=)
WO (1) WO2021235508A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523225A (ja) 2000-12-26 2004-08-05 リサーチ　ディベロップメント　ファンデーション 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２
US6548738B2 (en) 2000-12-26 2003-04-15 Research Development Foundation ACC2-knockout mice and uses thereof
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
WO2011058474A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
LT2776038T (lt) 2011-11-11 2018-04-25 Gilead Apollo, Llc Acc inhibitoriai ir jų panaudojimas
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
JP6205152B2 (ja) 2013-03-25 2017-09-27 サイプレス セミコンダクター コーポレーション シリアル通信システム、受信装置およびシリアル通信方法
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
EA201892201A1 (ru) * 2016-03-30 2019-03-29 Женфит Неинвазивная диагностика неалкогольного стеатогепатита
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds

Also Published As

Publication number Publication date
US20260091022A1 (en) 2026-04-02
JPWO2021235508A1 (https=) 2021-11-25
JP7820294B2 (ja) 2026-02-25
KR20230013126A (ko) 2023-01-26
CA3182134A1 (en) 2021-11-25
US12521375B2 (en) 2026-01-13
CN115666558A (zh) 2023-01-31
AU2021275292A1 (en) 2022-12-15
EP4154880A1 (en) 2023-03-29
EP4154880A4 (en) 2024-06-05
MX2022014553A (es) 2022-12-15
WO2021235508A1 (ja) 2021-11-25
US20230210822A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP6630374B2 (ja) τリン酸化を阻害する方法
WO2021068380A1 (zh) 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
JPWO2019013311A1 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
US20210130352A1 (en) Oga inhibitor compounds
BR122023011445B1 (pt) Inibidores de autotaxina e usos dos mesmos
CN101842100A (zh) 使用异噻唑并嘧啶酮刺激神经发生和抑制神经元变性的方法和组合物
TWI688565B (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
US20260091022A1 (en) Pharmaceutical composition for treating fatty liver disease
BR112020014320A2 (pt) Derivados de oxadiazolopiridina substituída por heterociclila para uso como inibidores de grelina o-acil transferase (goat)
JP2020111571A (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
JP2023546768A (ja) トランスサイレチン四量体を安定化するレチノール結合タンパク質４の二重特異性アンタゴニスト、その調製、および一般的な加齢関連合併症の治療における使用
US10889585B2 (en) Inhibitors of kidney-type glutaminase, GLS-1
TW202128686A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
US20230002317A1 (en) Novel small molecule shc blockers used for treating liver disease and metabolic disease
US12274703B2 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
US20250041279A1 (en) Therapeutic medicine for heart disease or skeletal muscle disease
US9187439B2 (en) Tricyclic compounds useful as neurogenic and neuroprotective agents
US20240417374A1 (en) Small molecule antagonist to pacap receptor and uses thereof
CN104109147B (zh) 羟基脒基苯类衍生物及其制备方法和医药用途
US20230348464A1 (en) Novel vdac1 inhibitors
TW202233605A (zh) 雙環嗒𠯤酮及其使用方法
CN112745319B (zh) 一类取代三环结构的化合物、其制备方法及用途
HK40082231A (en) Pharmaceutical for treating fatty liver diseases
HUE028725T2 (en) Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases
US20190177336A1 (en) THIENO[2,3-b]PYRIDINE DERIVATIVE AND QUINOLINE DERIVATIVE, AND USE THEREOF